Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Excellent News

<< Previous

Bullboard Posts

Next >>

Post by knoxton Nov 06, 2023 7:27am

512 Views

Post# 35718846

Excellent News

Theralase® (TSXV: TLT) has commenced a Listed Issuer Financing Exemption (“LIFE”) private placement financing for up to $CAN 5.3 M. Theralase(R) Announces Brokered LIFE Financing (tmx.com)

The Company is focused on providing the next standard of care treatment for bladder cancer (10^th most common cancer in the world, 6^th in men) which represents a potential market opportunity of approximately $USD 1 to 7 B annually.

Why Theralase®

Theralase is developing a paradigm-shifting Photo Dynamic Therapy (“PDT”) for treating BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”).
On October 16^th, the Company announced encouraging results with 65% of patients treated in the Phase-II pivotal trial achieving Complete Response (“CR”). Theralase(R) Provides Update on Bladder Cancer Clinical Study (tmx.com)
On October 23^rd, the Company optimized the design of the Phase II clinical study. Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study (tmx.com)
The Company enrolled and treated 63 out of 100 patients in an FDA Phase II clinical study; potentially granting Theralase® access to a cancer market worth $USD 1 to 7 billion annually, if regulatory approved
Interim data to date is trending better than current FDA approved treatments, Keytruda® (Pembrolizumab) and Adstiladrin®
Theralase® expects to apply for pre-Breakthrough Therapy Designation (“BTD”) before year end.

Terms:

Offer: LIFE offering for up to $5.3mm, $0.22 per Unit (1 common share + 1 full 5 year warrant; exercisable at $0.28 for 5 years)
Best efforts to list the warrant

If you wish to participate, please e-mail r white@theralase.com to receive the Investor Questionnaire for completion.

Note: For US-based retail investors, the LIFE exemption would not apply and there would be a 4 month hold on the common shares and warrants.

Note: Unfortunately, Quebec-based investors are not eligible for this LIFE financing.